Result for
Tag: vaccination
June 2, 2021
Mechanistic Modeling of SARS-CoV-2 Immune Memory Variants and Vaccines
[Pre-print, not peer-reviewed] The COVID-19 transmission model Covasim, with updated methods accounting for trajectories in immune response, SARS-CoV-2 variants, and vaccine roll-out, found that neutralizing antibodies (NAbs) correlated strongly with infection blocking. The model suggests Nabs elicited by natural infection may provide more protection than the same level of Nabs elicited by vaccines; however, vaccines…
June 1, 2021
The Indirect Effect of MRNA-Based Covid-19 Vaccination on Unvaccinated Household Members
[Pre-print, not peer-reviewed] Incidence of PCR-confirmed SARS-CoV-2 infection was 43% lower among unvaccinated spouses of healthcare workers (HCWs) vaccinated with mRNA vaccines (Pfizer-BioNTech and Moderna) 10 weeks after the first dose compared to spouses of unvaccinated HCWs, according to an analysis of national-level administrative data in Finland. The authors suggest that the vaccines may confer…
May 27, 2021
Accessibility and Usability of State Health Department COVID-19 Vaccine Websites
A qualitative evaluation of each US state’s department of health website content for vaccine eligibility and availability conducted in February 2021 found that of the 47 states providing eligibility information, 57% did not support eligibility verification, and 83% presented eligibility information at a post-high school reading level. Only half of all states provided web-based appointment…
Post-Vaccination SARS-CoV-2 Infection Risk Factors and Illness Profile in a Prospective Observational Community-Based Case-Control Study
[Pre-print, not peer-reviewed] Breakthrough SARS-CoV-2 infections after at least 14 days following the first dose of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines were less likely among those with healthier lifestyle factors. Findings were based on a case-control study of 2,394 individuals with a breakthrough infection matched 1:1 by age, sex, and other potential confounders to other…
May 26, 2021
Monoclonal Antibody Treatment Prophylaxis and Vaccines Combined to Reduce SARS CoV-2 Spread
[Pre-print, not peer-reviewed] A modeling study of SARS-CoV-2 transmission in the US population found that allocating monoclonal antibodies (mAbs) as post-exposure prophylaxis (PEP) and treatment of persons with COVID-19 in combination with a vaccination program could substantially reduce infections and mortality. Allocation of mAbs as PEP to persons >65 years of age averted up to…
May 25, 2021
Effectiveness of COVID-19 Vaccines against the B.1.617.2 Variant
[Pre-print, not peer-reviewed] Effectiveness of the Pfizer-BioNTech vaccine against symptomatic SARS-CoV-2 infection following 1 dose was 34% against the B.1.617.2 variant of concern (first described in India) compared to 51% against the B.1.1.7 variant in a case control analysis of 12,675 sequenced cases in England (92% B.1.1.7). Two-dose effectiveness was modestly lower, with 88% against…
May 21, 2021
Efficient Maternal to Neonatal Transfer of Antibodies against SARS-CoV-2 and BNT162b2 MRNA COVID-19 Vaccine
A multicenter study of pregnant persons in Israel (N=213) found that the Pfizer-BioNTech vaccine elicited strong maternal IgG response and produced similar IgG titers in the fetus 15 days after the first dose. Among study participants who were infected with SARS-CoV-2 during pregnancy, those infected in the third trimester had lower rates of antibody transfer…
May 20, 2021
Strategies That Make Vaccination Easy and Promote Autonomy Could Increase COVID-19 Vaccination in Those Who Remain Hesitant
[Pre-print, not peer-reviewed] A cross-sectional survey conducted among a representative US sample (n=2,895, 38% vaccinated) in March 2021 found that among those who were vaccine hesitant (n=522), major concerns were vaccine side-effects and efficacy (78%) and mistrust of the government or vaccines (38%). Among those with intent to initiate vaccination (n=1,326), most common barriers included…
Incident SARS-CoV-2 Infection among mRNA-Vaccinated and Unvaccinated Nursing Home Residents
The incidence of SARS-CoV-2 infections among a sample of residents of nursing homes in the US who received an mRNA COVID-19 vaccine (n=18,242, 80% Pfizer-BioNTech vaccine) decreased from 4.5% within 0-14 days after the first dose to 1.4% within 15-28 days after the first dose. Cases occurring 14 or more days after the second dose…
May 19, 2021
Disparities in COVID-19 Vaccination Coverage Between Urban and Rural Counties — United States, December 14, 2020–April 10, 2021
Vaccination for COVID-19 among US adults aged 18-64 years was lower in rural (39%) than urban (46%) counties as of April 10, 2021 according to administrative data reported to the CDC. Disparities persisted across age and sex. Among 46 health jurisdictions where urban-rural comparisons could be assessed, only 5 had higher coverage in rural counties…
Previous page Next page